but with less risk of bioprosthetic valve dysfunction, in patients with small annuli and symptomatic severe aortic stenosis. Presenting the data here at CRT 2025, SMART lead Investigator Howard ...
Hosted on MSN21d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the Small Annuli Randomized To Evolut or SAPIEN ... a small annulus can benefit from Evolut's differentiated valve design." AS is stated to be a widespread valvular heart ...
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT) released the two-year results of the SMall Annuli Randomized ... disabling stroke, and heart failure hospitalization, and continued superior valve performance ...
Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN ... trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients ...
At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and importantly no prosthesis-patient mismatch (PPM*) reported in these small annuli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback